Mariah
Osteosarcoma Survivor
Read Mariah's Story

Josh
Brain Tumor Survivor
Read Josh's Story

Sydney
Leukemia Survivor
Read Sydney's Story

Alijah
Leukemia Survivor
Read Alijah's Story

Rosie
Wilms Tumor Survivor
Read Rosie's Story

Ryan
Leukemia Survivor
Read Ryan's Story

Sydney
Retinoblastoma Survivor
Read Sydney's Story

Jakub Tolar, M.D., Ph.D.

Dr. Tolar is originally from the Czech Republic, where he received his medical education at the Charles University in Prague. In 1992, he came to the University of Minnesota to complete his Ph.D. in Molecular, Cellular & Developmental Biology and Genetics. He is currently an associate professor in the Department of Pediatrics, Blood and Marrow Transplantation, the Albert D. and Eva J. Corniea Chair, and the Director of Stem Cell/Gene Therapies.

Current focus

“In the laboratory, I have focused on stem cell gene therapy for tissue healing, on side effects of stem cell therapy, on novel non-viral gene therapy for correction of immunodeficiencies, and on biology of adult stem cell. In the clinic, our team has described improved conditioning for aplastic anemia and osteopetrosis, novel therapy for adrenoleukodystropy, and we’re focusing on reviewing data on transplant with adult stem cells for metabolic disease.”

Committed to finding a cure

“I have been driven to childhood cancer by the high price we pay when we fail, and by the intense focus needed to limit the risk of such failure. Despite major advances by the gifted scientists and clinicians who gave us a glimpse of success, there is no reason to believe that the search for a cure for childhood cancer has been completed. The ideal of cure is real, but only on the understanding that it is real with still-unknown complications.”

Children's Cancer Research Fund: Making a difference

“Children's Cancer Research Fund has made a difference by supporting the high-quality products of creative impulse, which is aimed solely at improvement in the care of children with cancer. It has provided seed money that often develops into larger translational grants, smaller grants aimed at answering a specific clinically relevant question, and funds for new equipment needed to advance childhood cancer research.”

Back to Meet Our Researchers